TD Cowen Trims Ascendis Pharma A/S (NASDAQ:ASND) Target Price to $157.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lowered by TD Cowen from $175.00 to $157.00 in a research report report published on Wednesday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an overweight rating in a report on Wednesday, August 21st. Wells Fargo & Company reduced their price objective on Ascendis Pharma A/S from $277.00 to $264.00 and set an overweight rating for the company in a research note on Wednesday. StockNews.com lowered Ascendis Pharma A/S from a hold rating to a sell rating in a research report on Tuesday, August 13th. Cantor Fitzgerald cut their price target on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an overweight rating on the stock in a report on Wednesday. Finally, Morgan Stanley increased their price target on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an equal weight rating in a research report on Thursday, May 16th. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $187.08.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $119.15 on Wednesday. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of -12.40 and a beta of 0.63. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The company has a 50-day simple moving average of $134.38 and a two-hundred day simple moving average of $138.20.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC purchased a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $25,000. Private Ocean LLC purchased a new stake in Ascendis Pharma A/S during the 1st quarter worth about $36,000. Quadrant Capital Group LLC boosted its stake in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares in the last quarter. Finally, Barometer Capital Management Inc. purchased a new position in Ascendis Pharma A/S during the 4th quarter valued at about $126,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.